| Dasatinib | Sprycel® (Bristol-Myers Squibb Company) | Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy | Drug Information Portal
|
| Imatinib mesylate | Gleevec® (Novartis Pharmaceuticals Corp.) | Treatment of chronic myelogenous leukemia | Drug Information Portal
|
| Interferon alfa-2a (recombinant) | Roferon®-A (Hoffmann-La Roche, Inc.) | Treatment of chronic myelogenous leukemia. | Drug Information Portal
|
| Nilotinib | Tasigna® (Novartis Pharmaceutical Corporation) | For the use for chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included Gleevec(imatinib) | Drug Information Portal
MedlinePlus |